Theravance Biopharma (TBPH) Short-term Investments (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Short-term Investments data on file, last reported at $106.6 million in Q1 2026.

• On a quarterly basis, Short-term Investments rose 426.48% year-over-year to $106.6 million in Q1 2026; TTM through Mar 2026 was $106.6 million, a 426.48% increase from a year earlier, with the FY2025 full-year figure at $147.6 million, up 191.87% from the prior year.
• Short-term Investments for Q1 2026 stood at $106.6 million, down from $147.6 million in the prior quarter.
• Over the last five years, Short-term Investments for TBPH reached as high as $154.9 million in Q3 2025 and fell as low as $20.2 million in Q1 2025.
• Historically, Short-term Investments has averaged $66.9 million across 5 years, with a median of $56.9 million in 2025.
• Across the five-year window, Short-term Investments plunged 64.9% in 2022 and surged 426.48% in 2026, its largest moves.
• Year by year, Short-term Investments stood at $29.3 million in 2022, then soared by 114.52% to $62.9 million in 2023, then retreated by 19.61% to $50.6 million in 2024, then surged by 191.87% to $147.6 million in 2025, then dropped by 27.78% to $106.6 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $106.6 million in Q1 2026, $147.6 million in Q4 2025, and $154.9 million in Q3 2025.